<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03092427</url>
  </required_header>
  <id_info>
    <org_study_id>P150934</org_study_id>
    <nct_id>NCT03092427</nct_id>
  </id_info>
  <brief_title>Probiotic Treatment in Juvenile Idiopathic Arthritis (JIA)</brief_title>
  <acronym>PERMAJI</acronym>
  <official_title>Evaluation of the Effectiveness of a Probiotic Treatment on Clinical Activity, Relapse Rates and Modification of the Intestinal Microbiota in Patients With Juvenile Idiopathic Arthritis (JIA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the efficacy of probiotic VSL#3 as an add on standard care on the
      activity of the disease in patients with Juvenile Idiopathic Arthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Juvenile Idiopathic Arthritis (JIA) is the most frequent rheumatic disorder in children.
      Numerous studies suggest that alteration of the intestinal barrier may induce abnormal immune
      responses implicated in development or persistence of arthritis. This paves the way to new
      therapeutic options aiming to reestablish intestinal homeostasis to treat arthritis or to
      prevent disease flares. This study investigates the efficacy of probiotic VSL#3 as an add on
      standard care on the activity of the disease in patients with Juvenile Idiopathic Arthritis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 4, 2017</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the impact of a regular intake of probiotic VSL#3 in addition to standard treatment in patients with JIA on the clinical activity</measure>
    <time_frame>3 months</time_frame>
    <description>American College of Rheumatology Pédiatrique score (ACR Pedi )</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the impact of a regular intake of probiotic VSL#3 in addition to standard treatment in patients with JIA on the intestinal microbiota.</measure>
    <time_frame>3 months</time_frame>
    <description>Stool samples for intestinal microbiota analyses</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Juvenile Idiopathic Arthritis</condition>
  <arm_group>
    <arm_group_label>Probiotic VSL#3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>VSL#3</intervention_name>
    <description>Dietary Supplement</description>
    <arm_group_label>Probiotic VSL#3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥1year and &lt;7years

          -  Patients with oligoarthritis and polyarthritis with rheumafactor negative and
             antinuclear antibodies (ANA) positive JIA with onset before the age of 6 years

        Exclusion Criteria:

          -  Change of JIA forme
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ulrich Meinzer, MD/PhD</last_name>
    <phone>33 1 40 03 20 48</phone>
    <email>ulrich.meinzer@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Albert Faye, MD/PhD</last_name>
    <phone>33 1 40 03 53 61</phone>
    <email>albert.faye@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Robert Debre Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrich Meinzer, MD</last_name>
      <phone>+33140032599</phone>
      <email>ulrich.meinzer@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2017</study_first_submitted>
  <study_first_submitted_qc>March 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2017</study_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Juvenile</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

